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Abstract The donors of human genetic resources deserve benefits in return for their 
contribution to scientific research. In the context of developing countries this claim 
holds as a matter of justice. But how can this demand be realised and implemented? 
This chapter looks at the role of ethics review as a possible benefit sharing mecha-
nism. In particular the promising role of research ethics committees in monitor-
ing the Declaration of Helsinki‘s post-study obligations is considered. However, a 
range of obstacles are identified, which would have to be overcome before ethics 
review could reliably achieve justice for the donors of human genetic resources in 
developing countries. These issues are addressed in specific recommendations. The 
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chapter concludes that the provision of health care, however extensive, in return for 
the donation of human genetic resources does not represent undue inducement, but 
rather fair benefit sharing.
Keywords  Benefit  sharing  •  Research  ethics  •  Developing  countries  •  Post-
study access  •  Declaration of Helsinki
8.1  Introduction
‘The arc of the universe is long, but it bends towards justice.’ This is how Martin 
Luther King Jr. expressed his hopes for the future. Of course, justice does not 
arrive of its own accord. Four years after receiving the Nobel Peace Prize in 1964 
for his non-violent work to advance civil rights King was assassinated. Today, 
there is a black President of the United States, giving an indication that some of 
King’s dreams of justice have been realized. However, when we turn to interna-
tional justice, we note that the US is one of a handful of countries1 that are not 
parties to the international Convention on Biological Diversity (CBD). In the pre-
vious chapter, an expansion of the CBD was suggested in order to achieve justice 
for donors of human genetic resources.2 This chapter will explore the potential for 
utilizing the existing, well-established system of ethical review to advance benefit 
sharing.
How does one protect human research participants from harm and exploitation? 
Four basic markers for the occurrence of harm in the research context can be dis-
tinguished (see Chap. 2).
1. Unfavourable risk-benefit ratio
2. Breach of confidentiality or privacy
3. Invalid consent
4. Lack of access to the benefits of research.
Exploitation is mainly relevant to the fourth marker and equates to ‘a failure to 
benefit others as some norm of fairness requires’ (Mayer 2007: 142) (see Chap. 2). 
Ethics committees have increasingly taken on the responsibility of preventing such 
exploitation. They appear in two main varieties: clinical ethics committees have 
been in existence since the early 1960s, mostly to support staff, patients and fami-
lies in making end-of-life decisions, while research ethics committees have been 
in existence since the late 1960s (see below) to govern research involving human 
participants (Aulisio 2003: 841).3
1
 Two exceptions at the time of writing are Andorra and South Sudan.
2
 By human biological resources, we mean human biological samples collected for genetic stud-
ies and related data.
3
 For more on clinical ethics committees see McGee et al. (2001), Kuczewski (2004), Slowther 
(2007) and ASBH (1998).
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
un
co
rr
ec
te
d 
pr
oo
f
Layout: T1 Standard SC Book ID: 311639_1_En Book ISBN: 978-94-007-6205-3
Chapter No.: 8 Date: 9-03-2013 Page: 3/23
38 Realizing Benefit Sharing: Is there a Role for Ethics Review?
Research ethics committees are most relevant to this chapter. Their primary role 
is to decide whether a particular research project is ethical or not by reviewing 
its study protocol. Such committees usually comprise scientists, professionals and 
lay people supported by an administrator. Standard questions for such a committee 
would be:
•	 Are the research participants appropriately informed?
•	 Is the balance of risks and benefits posed by the research fair and reasonable?
•	 Are the research participants likely to be worse off for participating in research? 
If so, does their consent represent a sufficient protection of their interests (or are 
they being exploited)?
•	 Is the research likely to be useful and informative? (Ashcroft 2007: 684)
Ethical review generally follows a particular pattern. Study protocols are 
received from researchers, and are then reviewed by a single member, a small con-
sultation team or the full ethics committee. Applications may be approved at that 
point; if not, they are returned to the applicant with queries before being reconsid-
ered and finally approved or rejected. The legitimacy of ethics committees derives 
from the fact that they are lawfully established and adhere to a process of delib-
eration as a diverse group of experts (including lay people) who reach consensus 
after discussion (Garrard and Dawson 2005: 423). While review requirements dif-
fer between (and sometimes within) countries, Fig. 8.1 shows the most basic steps.
In assessing whether a protocol is ethically acceptable, research ethics com-
mittees refer to international guidelines (e.g. the Declaration of Helsinki), national 
guidelines (e.g. UK Medical Research Council guidelines) and national law (e.g. 
National Health Council of Brazil resolutions). A research ethics committee there-
fore seeks to protect the interests of research subjects by ensuring compliance with 
ethical guidelines. Many countries (e.g. the US and the UK) have made it a criminal 
offence to start medical research without ethical approval from the relevant research 
ethics committee. This, de facto, gives ethics committees the role of a regulatory 
authority, a position with ‘immense power over the research that is carried out’ 
(McGuinness 2008: 695).
The Nuremberg Code (1949)4 and the World Medical Association’s Declaration of 
Helsinki: Ethical Principles for Medical Research Involving Human Subjects (1964) 
placed responsibility for safeguarding research participants on the investigator. In 
1975, however, the Tokyo revision of the Declaration of Helsinki introduced ethics 
committee review of research as its second basic principle (Levine 1995: 2312):
The design and performance of each experimental procedure involving human subjects 
should be clearly formulated in an experimental protocol which should be transmitted to 
a specially appointed independent committee for consideration, comment and guidance 
(WMA 1975).
AQ1
4
 The Nuremberg Code of 1949 is a set of principles and rules to be observed when undertaking 
research with human participants. It was developed after the Nuremberg trials in 1946 and 1947 
of Nazi doctors who had committed atrocities against concentration camp internees as part of 
medical research. It was superseded by the Declaration of Helsinki in 1964 (see Chap. 3).
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Since 1975, repeated revisions of the Declaration of Helsinki have specified in 
increasing detail what is implied by ethics committee review. Principle 15 of the 
current (2008) declaration reads:
The research protocol must be submitted for consideration, comment, guidance and 
approval to a research ethics committee before the study begins. This committee must be 
independent of the researcher, the sponsor and any other undue influence. It must take into 
consideration the laws and regulations of the country or countries in which the research 
is to be performed as well as applicable international norms and standards but these must 
not be allowed to reduce or eliminate any of the protections for research subjects set forth 
in this Declaration. The committee must have the right to monitor ongoing studies. The 
researcher must provide monitoring information to the committee, especially information 
about any serious adverse events. No change to the protocol may be made without consid-
eration and approval by the committee (WMA 2008).
Until the end of the twentieth century, ethics committee review concentrated 
on pre-start approval, but nowadays it is increasingly seen as a process that does 
not stop until the research has been completed. For instance, funding bodies such 
Fig. 8.1  Simplified Ethical Review Process
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as the Economic and Social Research Council in Britain see monitoring as a mini-
mum ethics requirement. The council’s Framework for Research Ethics includes 
the following:
Procedures for institutional monitoring should be in place. Universities and other research 
organisations should establish appropriate procedures to monitor the conduct of research 
which has received ethics approval until it is completed, and to ensure appropriate con-
tinuing review where the research design anticipates possible changes over time that may 
need to be addressed (ESRC n.d.: 5).
It would therefore be feasible for ethics review of a research project to con-
tinue up to the point at which it may be possible to determine whether vulnerable 
research participants, especially in developing countries, have benefited from tak-
ing part in research. To complement the Chap. 7, which recommended expanding 
the provisions of the CBD to include access and benefit-sharing arrangements for 
human biological resources, we will ask:
Could research ethics committees ensure compliance with post-study obligations (a form 
of benefit sharing), in order to avoid burdening medical research with further governance 
structures?
Before answering this question, it is worth revisiting and strengthening a claim 
made earlier (see Chap. 2), namely that the developing world should be treated 
differently from the developed world when it comes to the governance of human 
biological resources. The alleged altruism shown by European DNA donors, for 
instance, cannot be expected of donors from developing countries without perpetu-
ating exploitative relationships.
8.2  Benefit Sharing Versus the Altruism or Solidarity 
Model
For decades human tissue has been provided voluntarily by individuals for 
research purposes, in most cases without any expectation of benefit. The case of 
blood donation in the United Kingdom for blood transfusions and research pur-
poses is a case in point (Keown 1997). This altruism is also apparent among 
research participants in developing countries. In interviews undertaken with sex 
worker participants enrolled in long-term HIV/AIDS research in Majengo, Nairobi 
(see Chap. 5), one respondent said:
On my faith … they can get a cure from my blood and it can help the whole world. So 
that is why I gave myself. Even if I am infected…I am ready because I agreed to collabo-
rate in the research.5
This respo dent donated her blood to help the whole world. However, interna-
tional ethics guidelines (see Chap. 3) now require benefit sharing with research 
5
 Interview with Majengo participant in GenBenefit project, April 2007.
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participants. To recap, paragraph 14 of the Declaration of Helsinki (WMA 2008) 
requires as follows:
The protocol should describe arrangements for post-study access by study subjects to 
interventions identified as beneficial in the study or access to other appropriate care or 
benefits.
Hence, every research project which is presented for ethics approval must out-
line in its protocol how it will deal with post-study obligations. This is particularly 
important in the case of vulnerable populations, which is why the Declaration of 
Helsinki (WMA 2008) adds in paragraph 17:
Medical research involving a disadvantaged or vulnerable population or community 
is only justified if … there is a reasonable likelihood that this population or community 
stands to benefit from the results of the research.
The question arises: why should humans not be able to simply donate their 
tissue for the good of the world, without requiring burdensome and bureaucratic 
arrangements for post-study access to benefits? It seems that most people who pro-
vide blood or samples for research in the developed world are content to do so 
purely on the assurance that the tissue supplied will be utilized for the betterment 
of humankind. Why then should individuals from the developing world expect any 
more from the same transaction? No work is involved in producing DNA, nor do 
donors incur significant risks in donating samples. One could say that we need to 
draw upon the altruism of humankind to ensure the provision of resources that are 
so important for health research (Berg and Chadwick 2001: 320).
Altruism, which in its broadest sense means promoting the interests of another 
(Scott and Seglow 2007: 1), is an interesting concept. Under scrutiny it reveals 
complex questions about morality. For example, to donate one’s blood or organs 
with the proviso that they can only be given to those of one’s own race would 
be altruistic, but morally questionable. A UK government investigation found it 
‘abhorrent’ that a hospital had accepted an organ donation on condition that it ben-
efited a white patient (BBC 2000). Hence, acts of altruism might not always be as 
morally pure as they appear at first sight.
The eighteenth-century political economist Adam Smith maintained that ego-
ism or self-interest would lead to general welfare, stating that it was not ‘from 
the benevolence of the butcher, the brewer or the baker that we expect our din-
ner, but from their regard to their own interest’ (Smith 1976: 26f). On the other 
hand, French philosopher Auguste Comte, who coined the term ‘altruism’ in the 
early nineteenth century, believed that promoting other people’s interests meant 
that morality triumphed over egoism (Scott and Seglow 2007: 15). Immanuel 
Kant provided useful guidance on the motives behind altruism. He distinguished 
beneficence (Wohltun), which is understood as doing good, from benevolence 
(Wohlwollen), which is understood as wishing well. Beneficence is then benevo-
lence in action; acting in accordance with a ‘maxim of making others’ happiness 
one’s end’ (Kant 1996: 452). While this might appear noble in essence, the motive 
Kant provided for beneficence is actually close to self-interest. He claimed that 
one would not want to live in a world where those in need were not supported or 
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78 Realizing Benefit Sharing: Is there a Role for Ethics Review?
assisted, simply because one might require similar assistance from others in the 
future.
This scenario of individuals mutually acknowledging their human needs and 
subsequent duties has been called the duty of mutual aid (Herman 1993). In this 
context, reciprocity and expectations are important. Such reciprocity protects the 
altruist, even though it might provide a less than perfectly noble motive for her 
good deeds. Reciprocal altruism is performed in the hope of obtaining a future 
reward, for instance in the form of assistance, and is therefore something of a 
hybrid between altruism and self-interest.
Reciprocity was examined by Marcel Mauss in his classic 1950 anthropologi-
cal study The Gift (2002). Mauss examined gift-giving in ancient times and in 
more recent Roman, Jewish, Germanic and other Indo-European societies. The 
seemingly ubiquitous practice of gift-giving existed separately from commer-
cial transactions in all these societies. He defined a gift as ‘a voluntary, unre-
quited surrender of resources’ (Mauss 2002: 3). The apparent generosity of the 
gifting practices seemed to indicate very high levels of solidarity, charity and 
trust. However, Mauss famously concluded that in all such societies there were 
no free gifts. The giving of gifts engaged the giver and the receiver alike in finely 
woven, if implicit, obligations and commitments that reflected and resonated 
with the institutions of the day. Morality did not seem to enter the transaction, 
and the society’s (unwritten) norms and expectations framed what was required 
in certain circumstances. Mauss established that the entire notion of a free gift 
was based upon a misunderstanding of the nature of such a transaction, and con-
cluded that a gift that expected no return, that did nothing to enhance solidarity, 
was a contradiction in terms (Mauss 2002: xii). His work encourages us to con-
sider that material items, whether sold or given, always retain something of the 
identity of the giver, and often require reciprocation in some form.
The work of Richard Titmuss added significantly to the understanding of altru-
ism. In his book The Gift Relationship (1997) he attempted to counter policies that 
promoted the commodification of human blood. His primary aim was to advocate 
voluntary blood donation, which allowed people the moral choice to give blood as 
a ‘symbolic gift of life to an unnamed stranger’ (Titmuss 1997: 140). What might 
be regarded as particularly altruistic was that the gift of blood was to unknown 
individuals. Hence, it was not given to those in close relationships to whom, in 
Mauss’s societies, one might turn in times of need. The only reward for the donors 
was the knowledge that they had contributed to the public good.
One of Titmuss’s most powerful arguments was that the opportunity to behave 
altruistically was an essential human right. He believed that specific instruments 
of public policy were able to harness and encourage that crucial element of altru-
ism in opposition to the ‘possessive egoism of the marketplace’ (Titmuss 1997: 
59). His plea was that people should be enabled to choose to give to unnamed 
strangers, and not be ‘constrained by the market’ (Titmuss 1997: 310). However, 
whether the donation of blood is a true gift that expects no return, or instead crea-
tive altruism that fosters a sense of belonging to a community of assistance, is dif-
ficult to establish (Scott and Seglow 2007: 111).
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Titmuss’s plea has been echoed in more recent appeals for altruistic donation 
(or solidarity) in the context of genetic research. Kåre Berg and Ruth Chadwick 
talk about a ‘duty to facilitate research progress and to provide knowledge 
that could be crucial to the health of others’ (Berg and Chadwick 2001: 320). 
Solidarity and equity are suggested as frameworks or paradigms in which the 
emphasis is on the duty of individuals and communities to participate in health 
research for the benefit of others. This approach might, however, contradict the 
post-study obligations outlined in paragraphs 14 and 17 of the Declaration of 
Helsinki (WMA 2008), as quoted above, given that these require benefit sharing.
Berg and Chadwick give two main reasons for preferring a solidarity frame-
work over benefit sharing. First as noted above, no work is required to produce 
DNA or blood:
The populations, families and individuals, whose samples have formed the basis for new 
products and revenue, have not themselves done anything to make their samples ‘valu-
able’… If anything, their samples have become valuable because of work conducted by 
scientists (Berg and Chadwick 2001: 320).
Second, ‘the emphasis on distribution of benefits might be seen not as an exer-
cise in … justice, but as an attempt to buy people off’ (Berg and Chadwick 2001: 
321). The implication of ‘buying people off’ is that providing specific benefits to 
donors would entail the risk of unduly influencing individuals to participate in 
research. Such undue inducement is prohibited by almost all ethics guidelines, 
as is the commodification of the body (i.e. the possibility of obtaining money in 
return for body parts or bodily tissue).
It is difficult to see how the first point could be justified morally. At first it appears 
as if it might be based on John Locke’s widely accepted labour-desert theory. He 
argued in the seventeenth century that ownership can be achieved if one mixes one’s 
labour with otherwise unowned objects. In the Second Treatise on Civil Government 
he writes: ‘As much land as a man tills, plants, improves, cultivates, and can use the 
product of, so much is his property’ (Locke 1690: Chapter V, ‘Of Property’, sec-
tion 32). For instance, if one looked after raspberry bushes on unowned land, one 
might be able to declare ownership of the bushes after a period of time. But the 
basis for Locke’s theory is his belief that we all own our individual bodies. Hence, 
the labour of geneticists is not mixed with unowned objects. Besides, if the sam-
ples were not valuable in themselves, there would be no interest in obtaining them. 
Assuming that value is only added later is reminiscent of debates prior to the adop-
tion of the CBD. Vandana Shiva (2005: 15) wrote in this context:
[It is assumed] that prior to prospecting, the resources of desire were unknown, unused 
and without value. Using terminology derived from earlier ‘prospecting’ for minerals and 
fossil fuels, ‘bioprospecting’ obscures the fact that living resources are not non-renewable 
and are not without value prior to exploitation by global commercial interests for global 
markets.
Hence, to assume that value is only created through doing something with a 
resource, as scientists might, risks falling back into pre-CBD exploitative practices 
in relation to accessing the resources of developing countries. With the adoption of 
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the CBD, it has been legally accepted that natural resources in developing coun-
tries are not unowned, only to become valuable with added (Western) labour. The 
fact that nobody has ‘made’ their own DNA is not therefore in itself an objection 
to benefit sharing.
The objection to benefit sharing which arises from prohibitions against undue 
inducement and commodification of the body is more serious. At the same time, it 
must be understood that benefit sharing does not mean handing over cash for DNA 
samples, which could be regarded as straightforward commodification. The CBD’s 
Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable 
Sharing of Benefits Arising from their Utilization (see Chap. 2) lists considera-
bly fewer monetary than non-monetary benefits. The latter include collaboration 
in scientific research, collaboration in education and training, institutional capac-
ity-building, access to scientific information, contributions to the local economy, 
research directed towards priority needs, such as health and food security, liveli-
hood security benefits and social recognition.
This brings us to an important point that helps us explain why research par-
ticipants in the developing world should be treated differently from those in devel-
oped countries in relation to the governance of human biological resources. DNA 
donors from Northern countries generally benefit automatically from education 
and livelihood security benefits. Those contributing to medical research in the 
North can usually rest assured of (see Chap. 2):
•	 Access to ever-increasing numbers of medical interventions to achieve and 
maintain health, which are tailored to local health needs and (in principle) 
accessible to all
•	 Increased knowledge about human health, which is made available to citizens 
through general education or health campaigns.
Hence, the ‘altruistic’ donor in the North could be regarded as part of a com-
munity which offers a fair exchange model to such donors. People experience a 
tangible form of reciprocity for their participation in the complex social and eco-
nomic network encompassed by the health care system, reminiscent of a Maussian 
society, ensuring the fairness of the entire exchange. Assured of far more than the 
mere cup of tea and biscuit traditionally received by blood donors since Titmuss’s 
time, individuals from affluent countries might appear to be acting out of solidar-
ity with their group, but their ostensible altruism is strongly bolstered by the fact 
that their contribution is virtually risk-free, and reciprocation is provided through 
the assurance of fair compensation via the health care system.
It is still the case that others may free-ride (type 1 exploitation, see Chap. 2) 
on the willingness of research participants to donate their time or even take risks. 
In this regard, Berg and Chadwick (2001) are right to appeal for more solidarity 
within communities. But it would be highly exploitative to demand such solidar-
ity from donors who are outside the fair exchange model and who contribute their 
DNA without receiving any benefit in return. Participants from an impoverished 
developing country are assured of none of the above benefits, and the use of their 
donated genetic material for the benefit of affluent, distant strangers deserves 
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critical attention, which returns us to the question: could research ethics commit-
tees ensure compliance with post-study obligations (a form of benefit sharing), in 
order to avoid burdening medical research with further governance structures?
As African bioethicist Godfrey Tangwa notes:
In medical research the principle of justice demands fairness in the treatment of individu-
als and communities and the equitable distribution of the burdens and benefits of research. 
This has important implications for such issues as … post-study benefits, and long term 
access or distribution of the benefits of the study. These are the issues, which preoccupy 
every research ethics committee sitting to review a health research protocol in Africa 
today (Tangwa 2009: S5).
When assessing the question of how justice might be secured within current 
regulatory frameworks, it is essential to distinguish between two types of bene-
fit-sharing arrangements which have different compliance challenges associated 
with them. First, we shall consider obstacles to enforcing post-study obligations 
which aim to provide a successfully tested health care intervention to research 
participants after the study has been concluded. We term this duty ‘post-study 
access’. Second, we shall analyse obstacles to enforcing the provision of benefits 
not directly linked to the study, such as access to health care, support for the local 
health infrastructure or health information campaigns. These will be referred to as 
‘other benefits’. We shall discuss first the challenges that apply to both benefit-
sharing types, and then those that apply exclusively to either type.
8.3  Post-study Access and Other Benefits
The following challenges to implementing a benefit-sharing framework of post-
study obligations apply both to giving research participants access to successfully 
tested interventions and to the provision of ‘other benefits’.
8.3.1  Whose Duty?
The Declaration of Helsinki does not specify whose obligation it is to discharge 
post-study obligations. Is it the duty of individual researchers? After all, they are 
the interface between sample donors on the one hand and research studies on the 
other. They are also the ones with the most to gain, aside from research partici-
pants. Unlike physicians, whose prime duty is the promotion and safeguarding of 
patient health, researchers have potentially competing obligations to their spon-
sors, as well as aspirations to achieve scientific progress.
While the Declaration of Helsinki clearly stipulates that ‘[i]n medical research 
involving human subjects, the well-being of the individual research subject must take 
precedence over all other interests’ (WMA 2008: paragraph 6), such ‘other interests’ 
cannot be ignored altogether. What is, however, identical in the two relationships – that 
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between doctor and patient and that between researcher and research participant – is 
that trust plays a major role and the relationship is often highly personal.
The breaking off of a relationship between researcher and research participant 
can be very difficult, even traumatic. If, as is frequently the case in the developing 
world, participation in a research study is the only way to access health care, then 
the end of a study implies the end of health care. In particular, researchers work-
ing with AIDS patients often find it difficult to withdraw in the knowledge that 
those patients are likely to die from a treatable disease (Shapiro and Benatar 2005: 
45). Needless to say, the sense of abandonment for the research participant is even 
stronger, especially when the study provided the only access to health care. In the 
worst cases, the end of the research results in death.
It is in this context that post-study obligations to research participants are advo-
cated. Focus group research conducted among patients, clinical researchers and 
research administrators in Kenya showed that all stakeholders believed strongly 
that researchers had a long-term obligation to participants. ‘The rationale behind 
this belief – whether fear of death, inability to continue therapy, or an ethical 
obligation – warrants attention’ (Shaffer et al. 2006: 55). Focusing on the ethical 
obligations, one would argue that research participants, having contributed to the 
advancement of knowledge, deserve some benefit in return. This aligns with the 
argument for non-exploitation as advocated throughout this book.
Importantly, though, a number of participants in the focus groups noted spe-
cifically that the loss of access to health care would result in a general loss of trust 
between research participants and researchers, potentially making the community 
unwilling to participate in research at all (NBAC 2001: 59). Both sides consider 
it unacceptable to abandon, at the end of a study, research participants who are in 
dire need of medical attention.
In terms of who has how much invested in the relationship, it might there-
fore make sense to allocate post-study obligations to researchers. However, these 
could also be among the duties of research funders and sponsors, who, one would 
assume, are best placed to find the resources to discharge such obligations.
One of the few countries with binding national law on post-study obligations 
is Brazil (see Chap. 3). In 1997, a resolution by that country’s National Health 
Council set the following stipulation:
Access to the medicine being tested must be assured by the sponsor or by the institution, 
researcher, or promoter, if there is no sponsor, in the event its superiority to the conven-
tional treatment is proven (National Health Council 1997: article IV.1(m)).
The Declaration of Helsinki lacks a similarly clear assignment of duties to a 
specified group. One might argue that this allows the flexibility needed in guide-
lines that must apply all over the world. In practice, however, this flexibility is 
partly responsible for the ineffectiveness of the guideline and the concomitant lack 
of good practice examples for post-study obligations. If the commitment to benefit 
sharing re-emphasized in the 2008 Declaration of Helsinki is to be effective, then 
research ethics committees need to know whose duty it is to provide access to suc-
cessfully tested interventions or ‘other benefits’ in order to ensure compliance.
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8.3.2  Insufficient Capacity for Review
Concerns about workload and personnel resources are factors that detract from 
the effectiveness of research ethics committees even in affluent settings (Schuppli 
and Fraser 2007). It is therefore not surprising that ethics committees in develop-
ing countries often lack the resources to give adequate attention to ethical review. 
A study published in 2009 that examined the effectiveness and training needs of 
African research ethics committees concluded that the ‘major constraints identi-
fied are shortage of resources and inadequate training of the ERC [ethical review 
committee] members’ (Nyika et al. 2009: 193). The study also summarized the 
constraints hindering the adequate review of study protocols in African settings. 
Table 8.1 lists the constraints in order of perceived gravity: that is, the first con-
straint is the one noted by the highest number of respondents.
Other studies have also shown that ‘the capacity to conduct ethical review in 
developing countries needs to be developed or enhanced’ (Hyder et al. 2004). 
Evidently, insufficient resources, lack of expertise and so on can render the protection 
of human research participants unreliable or even non-existent. Under these circum-
stances, it is unlikely that research ethics committees in developing countries would 
be in a position to enforce the requirement of benefit sharing. In order to carry out 
this task, they would need investment in both infrastructure and training. As the next 
subsection will show, this issue is particularly problematic when research ethics com-
mittees in the country of the research funder or sponsor are likely to ignore the obli-
gation. Encouragingly, though, a funding stream from the European and Developing 
Countries Clinical Trials Partnership is successfully funding the establishment of new 
ethics committees in Africa and capacity-building for existing committees.6
8.3.3  US Withdrawal from Post-study Obligations
The previous chapter suggested that an expansion of the provisions of the CBD to 
include human biological resources would close an important gap in the interna-
tional legal framework. It would establish an inclusive approach to biodiversity, 
both human and non-human, bring legal clarity to a contentious area and, most 
importantly, provide a way forward when a spectrum of genetic resources are used 
by various industries (e.g. when a product is developed using plant and human 
genetic resources).
As noted in the beginning of this chapter, the US is virtually the only country 
that is not a party to the CBD. At the same time, the US is the leading innovation 
economy in the world. For instance, the 2011 World Intellectual Property Indicators 
showed that 24% of all patents world-wide were granted by the US Patent and 
Trademark Office (WIPO 2011). In 2008, however, the US government effectively 
6
 See the partnership’s website at http://www.edctp.org.
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opted out of the Declaration of Helsinki when the US Food and Drug Administration 
discontinued its reliance on the declaration and issued independent Guidelines for 
Good Clinical Practice. The new guidelines omit the two standard benefit-sharing 
principles of the Declaration of Helsinki, namely post-study access to successfully 
tested interventions and the requirement that research, particularly in developing 
countries, must benefit local communities and be responsive to local health needs 
(Kimmelman et al. 2009). This means that US government requirements for the treat-
ment of research participants are now in direct conflict with the prescriptions of the 
Declaration of Helsinki (aside from the fact that the US is not a party to the CBD).
This development could mean that US research ethics committees (or institutional 
review boards) will in general put less pressure on researchers to describe compliance 
with post-study obligations in study protocols than their international counterparts 
that fully subscribe to the Declaration of Helsinki. While this is a serious concern, 
resource provider states are not entirely powerless in relation to compliance where 
they rely on ethics review. US researchers, like any others, require local ethics review 
in order to access human genetic resources. Such local ethics review (for instance 
in Kenya, Thailand or Bolivia) can, if well informed and decisive enough, provide 
approval only on condition that benefits to research participants and local communi-
ties are explicitly articulated. This strategy presents a distinct advantage over CBD 
expansion. In fact, strong ethics committees or national legislation in developing 
countries (see for instance Brazil’s benefit-sharing legislation as outlined in Chap. 3) 
can enforce benefit-sharing compliance now, without additional legal frameworks.
8.3.4  Timeliness of Research
A related advantage of utilizing ethics review to achieve benefit-sharing compli-
ance is that the procedure needs to be undertaken by researchers in any case. For 
instance, informed consent documentation and risk-benefit ratios will always be 
checked by an ethics review committee whether or not benefit sharing is also regu-
lated through independent mechanisms. Adding benefit-sharing information to that 
Table 8.1  Constraints on African Research Ethics Committees
Insufficient resources
Expertise on ethical review lacking
Pressure from researchers
Lack of active or consistent participation by members
Lack of recognition of importance of committee functions
Lack of support from institute concerned
Insufficient independence
Pressure from sponsors
Unequal treatment of applicants in review
Source Nyika et al. (2009) (modified)
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already required in the protocol in terms of the Declaration of Helsinki puts only a 
limited extra burden on the existing approval process.
Assuming that benefit-sharing requirements for human research participants 
were to be regulated through the CBD framework, another approval process would 
have to be added. According to Laird and Wynberg (2008), ‘[t]he negotiation of 
consent and benefit sharing agreements between those who access and those who 
provide non-human genetic resources takes on average 1–2 years and sometimes 
longer’ This would be a significant additional burden with considerable impact on 
the timeliness of research. Especially in health research, such delays can be highly 
detrimental to global public health and individual patients.
8.4  Post-study Access
The constraints we have listed so far concern enforcing the rovision of post-study 
access to successfully tested interventions and ‘other benefits’. However, some 
challenges are limited to ensuring post-study access.
8.4.1  Unrealistic Timeframe for Post-study Access
By the time a post-study obligation becomes relevant, some of the researchers 
involved are likely to have left the study site and even the country. In ‘helicop-
ter research’ (flying in and out of locations, for instance in a current epidemic), 
researchers leave as soon as the data is obtained. Many research units have long-
standing collaborations with host countries, but some do not, leaving research eth-
ics committees with no recourse to researchers after the completion of their study. 
In any case, it takes on average a decade to bring a drug to market (Trade and 
Industry Select Committee 2002). To be required to return to participants a decade 
after the study to see whether they are in need of the developed intervention is 
rather unrealistic and cumbersome to say the least. More importantly, for the pur-
poses of this chapter, it would be highly unrealistic to expect research ethics com-
mittees to ensure compliance ten years after a project’s completion.
8.4.2  Inbuilt Unfairness in Post-study Access: The Research 
Participant
Research ethics committees aim to protect all human research participants from 
exploitation, not just some.
Failure rates in drug development are extremely high. Of those developments 
that make it into clinical trials, 38% fail Phase I (safety), 60% of the remainder fail 
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Phase II (basic efficacy), 40% of the rest fail Phase III (comprehensive efficacy) 
and 23% of those still in the running will not be approved by the relevant health 
agency (Lowe 2004). As a result, the chances for any individual participant that 
the particular research she or he was involved in will actually lead to a marketable 
product are very slim, particularly for donors of biological materials in the early 
phases of research, and participants in Phase I and II drug trials.
Even if post-study access could be assured a decade after a study’s completion, 
it would only benefit those research participants lucky enough to have been part of 
bench-to-bed research which overcame all hurdles smoothly. But since those whose 
participation shows that a product is unsafe or not efficacious contribute as much to 
medical research as their luckier counterparts, one cannot argue that only the latter 
are entitled to benefit sharing – and there is no way to predict which participants 
will fall into which category. By the time a research ethics committee can establish 
which participants will not have an option of post-study access, it is likely to be too 
late to ensure any other benefits either. The committees are therefore restricted in 
their ability to provide equitable protection for all research participants.
A related problem is that of involvement in basic research, which is not likely 
to lead directly to any new medical interventions. In this case, however, research 
ethics committees could opt for the choice of ‘other benefits’ from the start.
8.4.3  Inbuilt Unfairness in Post-study Access and Possible 
Side Effects
It has been argued that imposing post-study obligations on researchers or their spon-
sors could mean that developing country research focused on local health needs 
would not be undertaken due to prohibitive costs (Brody 2002: 2857; McMillan 
and Conlon 2004: 206). One could respond with Solomon Benatar that ‘[r]equiring 
greater sensitivity to the plight of the poor and some degree of solidarity with them 
is not an excessive moral requirement’ (Shapiro and Benatar 2005: 42).
However, this could mean that attempts to achieve compliance with the ben-
efit-sharing regulations of the Declaration of Helsinki in order to achieve justice 
for resource providers in line with the CBD might be self-defeating. Currently, 
the demand to provide post-study access to successfully tested interventions 
applies equally to researchers who are using charitable funds to develop drugs 
for neglected diseases that only exist in, say, South East Asia, and pharmaceuti-
cal companies running clinical trials in developing countries for diseases that are 
prevalent and widespread in the North. However, the former is arguably not a case 
of exploitation, whereas the latter could be. Benefit sharing is intended to be an 
instrument to mitigate such exploitation. Yet if the mechanism is so coarse that it 
makes valuable (and arguably non-exploitative) research prohibitively costly, then 
enforcing benefit sharing through ethics review could undermine global efforts to 
realise access to locally tailored health care. In this case, the global injustice in 
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terms of access to health care could deepen rather than lessen, and concentrating 
on smaller details could cause the bigger picture to be overlooked.
Based on the three challenges to post-study access discussed above, one could 
venture that ‘other benefits’ may be a more promising and consistent benefit-shar-
ing tool for research ethics committees to require.
8.5  Other Benefits
In practice, when benefit sharing is addressed through ethics review, ‘other ben-
efits’ are generally thought to be a more realistic arrangement than post-study 
access. The most common example of this type of benefit sharing is access to 
health care during a study, as was and is the case for the Majengo sex workers (see 
Chap. 5). However, there are two problems here.
First, the latest (2008) Declaration of Helsinki may inadvertently have 
restricted the use of ‘other benefits’ as a benefit-sharing mechanism. The 2004 
declaration required study protocols to include information on post-trial access or 
‘other benefits’, and imposed no restrictions on what might constitute ‘other ben-
efits’. It did not exclude, for example, health care during or after a study. By con-
trast, paragraph 33 of the 2008 declaration states:
At the conclusion of the study, patients … are entitled … to share any benefits that result 
from it, for example, access to interventions identified as beneficial in the study or to other 
appropriate care or benefits’ (WMA 2008: paragraph 33) (our emphasis).
This formulation aligns with the general usage of terms, as one usually speaks 
of post-study obligations. However, it means that comprehensive health care deliv-
ered during a study, even a longitudinal study, is no longer included under ‘other 
benefits’ as a benefit-sharing mechanism.7 Yet many of the Nairobi sex workers 
interviewed in the course of our research indicated that access to health care was 
an important benefit they received in return for donating samples (see Box 8.1).
7
 Of course, one could argue that comprehensive health care during a study offers too little in 
terms of benefit sharing. However, where comprehensive health care is offered to study partici-
pants and their families, sometimes for decades, as is the case with some Nairobi sex workers, 
the fair exchange model available to donors from affluent countries is being approximated.
Box 8.1 Comments from sex workers in Majengo on the provision of free 
health care8
•	 I don’t pay for the medicine, I don’t do anything with respect to them, but 
they give me medicine. When I get some little ailment, they help me.
•	 I came and joined the clinic and I have been helped a lot. I used to have 
8
 Interviews with Majengo research participants, GenBenefit, April 2007.
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bad headaches, you know when your immunity goes down you get other 
ailments and they are worse than normal … but once you know your sta-
tus you can come and be treated quickly before it gets worse… So I’m 
grateful to this clinic, it has done us a lot of good.
•	 Yes, treatment. I get it for free; if they want to carry out some research 
and they need blood they give us bus fare because the appointed day may 
come to take your blood or urine sample and you may not be able because 
you don’t have bus fare.
•	 I expected treatment, free of charge. Every time I fall sick I come for 
treatment and it’s free.
•	 They just passed by telling people on the streets, and I learned there is 
a clinic for helping people to detect diseases and in return they use your 
blood for research. We agreed that it is OK.
•	 You see, they usually check us down there to see how we are getting on; 
you could be developing something. So you get to know about it early 
enough and save yourself. That for me is a benefit.
•	 No, I did not expect money or such things, just treatment.
•	 They give us free medicine because of the nature of our work. If you have 
a problem they help you.
•	 Because that is what I need. That is what is important, they give me what 
I would otherwise not be able to get [treatment].
•	 I was told I would get benefits of [testing for and treatment of] communi-
cable diseases. If I am found with them, I would be treated, there is a doc-
tor here, and there is medicine…
•	 Yes, I am satisfied because when I come here I get a cheerful doctor who 
I can confide in without fear and tell her about my pains, and when I have 
problems there is a counsellor I can go and talk to and [s]he counsels me 
until I am satisfied… I like this clinic because since we realized the ben-
efits of the clinic, we try to bring many people so that they too can ben-
efit. And the benefits I get from this clinic have also helped me in doing 
my work. I can protect myself against infections according to how we are 
advised at the clinic and I also teach others so that they can protect them-
selves too.
•	 We have a very nice doctor, sisters, they all welcome us in the clinic.
•	 For me I see that the benefits I would expect is treatment because what-
ever kind of sickness I get I am treated. So this clinic has a lot of benefits.
•	 I don’t think there should be any other kind of benefits … we are given 
free medicine, free treatment.
•	 I think it’s forever, because there are some women I have heard saying 
they have been here since 1986. So it can go on forever, that is so long as 
you are going to sponsor it [Interviewer: So you will be getting these free 
services forever?] Yes, hopefully! God willing. [Laughter].
•	 I don’t know what I will do if they close down.
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If the emphasis in the Declaration of Helsinki is on post-sharing of benefits, 
some of the challenges of securing post-study access (for example, the unrealistic 
timeframe) would now also apply to ‘other benefits’. In other words, if only those 
benefits delivered after a study is completed count towards benefit sharing, seek-
ing compliance through an ethics review committee could become difficult, as the 
committee usually ceases its monitoring work once the research is complete.
Second, offering access to health care as a benefit to participants could violate 
undue inducement prohibitions, a topic we have considered before (see Chaps. 2 
and 5). When undertaking research on economically disadvantaged or otherwise 
vulnerable populations possibly suffering from hunger or malnutrition, and lack-
ing access even to elementary health care, any prospect of health care (for exam-
ple, a general check-up as part of being enlisted in a study) can be regarded as 
an undue inducement. It is no surprise that UNESCO’s Universal Declaration on 
Bioethics and Human Rights includes two requirements of benefit sharing: first, 
that ‘[b]enefits resulting from any scientific research and its applications should be 
shared with society as a whole and within the international community, in particular 
with developing countries’, but, secondly, that those ‘[b]enefits should not consti-
tute improper inducements to participate in research’ (UNESCO 2005: article 15).
Some international guidelines, such as the International Ethical Guidelines 
for Biomedical Research Involving Human Subjects issued by the Council for 
International Organizations of Medical Science (CIOMS), accept that research 
participants may receive free medical services. However, CIOMS also notes that 
these services should not be ‘so extensive as to induce prospective subjects to con-
sent to participate in the research against their better judgment’ (CIOMS 2002: 
guideline 7). And research has shown – unsurprisingly – that the need to access 
medical services can amount to pressure to join research studies in developing 
countries. One cannot reliably determine how many participants actually take part 
‘against their better judgement’, but it is clear that many feel they effectively have 
no choice. As one of the Majengo research participants said, ‘I don’t know what I 
will do if they close down.’
When 347 Ugandan parents with children enrolled in a malaria study were 
asked whether they had felt coerced to join, more than half said they had ‘felt 
pressure to enrol their children because of the child’s sickness’ (Pace and Emanuel 
2005). As Annas and Grodin (1998) have formulated it,
in the absence of health care, virtually any offer of medical assistance (even in the guise 
of research) will be accepted as ‘better than nothing’ and research will almost inevitably 
be confused with treatment.
Ironically, strict prohibitions against undue inducement lead to a rather para-
doxical result. The poorer a community is, the smaller the benefits that can be 
offered without potentially exercising undue influence on the decision to par-
ticipate. The conflict here occurs because participants are meant to be protected 
against undue inducement on the one hand and exploitation on the other. Yet limit-
ing benefit-sharing possibilities gives research sponsors who outsource research to 
developing countries a convenient ‘ethical’ argument for limiting the benefits to 
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study participants (Ballantyne 2008: 190). As long as this paradox remains unre-
solved, ethics committees will not be in a position to decide definitively whether 
the ‘other benefits’ in a given case constitute benefit sharing or an undue induce-
ment. This makes it extremely difficult for committees to play their governance 
role successfully.
The authors of this chapter are continuing their research on the potential ten-
sion between benefit sharing for human genetic resources and undue inducement. 
They are already satisfied, however, that it is possible to provide benefit sharing 
while avoiding undue inducement. The commodification of the body can indeed 
open up further opportunities for exploitation, especially in developing coun-
tries. An example would be paid surrogate pregnancy, when Indian mothers, for 
instance, carry babies for affluent mothers in the North (Taneja 2008). But such 
commodification can be avoided by prohibiting one-to-one financial gain from a 
research transaction. If individual donors for DNA were given no cash except for 
legitimate expenses, the risk of undue inducement would be much reduced.
What, then, might legitimate benefit sharing that avoids undue inducement look 
like? Here it is important to look at two of the main reasons for legislating against 
undue inducement (see Chap. 2): namely, that research participants might accept a 
risk (usually to their health) that would not otherwise be acceptable, and that they 
would then participate in research against their better judgement.
It has already been noted that the donation of human genetic resources carries 
minimal risk and imposes a minimal burden.9 Hence, the foundation of the undue 
inducement principle does not apply to access to genetic resources in the same 
way as it applies to enrolling in Phase I clinical trials. If risk reduction can only be 
achieved by restricting benefits to research participants (as, for instance, in bur-
densome, risky trials involving healthy volunteers), minimal risk studies can con-
centrate more on benefit sharing than misplaced concerns about undue 
inducement. Access to health care for research participants and their local commu-
nities is therefore the ideal benefit to be shared with the donors of human biologi-
cal resources. Through such benefit sharing, they would come one step closer to 
the fair exchange model that exists between medical researchers in the North and 
their research participants. Global research without borders would then contribute 
to global justice without borders when it comes to access to health care. At least 
some additional access to health care, some new health care facilities and some 
health care training and education could be achieved this way.
At the same time, it is essential to note that benefit sharing cannot resolve deep-
seated issues of distributive injustice or human rights issues that render national 
governments unable to respect, protect, and fulfil the human right to access to 
health care. For this reason, we shall present in Chap. 9 an example of a reform 
plan that provides a way forward for increasing the availability of life-saving med-
icines for the poor, with the potential to close the health care gap between develop-
ing and developed countries.
9
 Some exceptions, as outlined in Chap. 2 xx, would have to be dealt with separately, for 
instance where blood might have sacred meaning.
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8.6  Conclusion
Can compliance with benefit-sharing obligations as outlined in the Declaration of 
Helsinki be achieved through ethical review? As we have seen, the obstacles are 
manifold. In particular, post-study access does not seem to be a promising sce-
nario, given the unrealistic timeframes and the potential for injustice. ‘Other bene-
fits’ are a more realistic option, in particular the provision of comprehensive health 
care during long-term studies. In order to strengthen the capacity of ethics review 
to ensure benefit sharing, we submit the following recommendations:
•	 Research ethics committees and other parties need to know whose duty it is 
to discharge post-study obligations. This could be specified in the Declaration 
of Helsinki, Specification in national law (as in Brazil) is another possibility. 
Solutions should be integrated with local health systems in developing countries 
so that research sponsors and local authorities understand their specific roles in 
providing health care to populations.
•	 Effective research ethics committees require adequate resources, training and 
time to fulfil their important roles. As studies have shown, this cannot be taken 
for granted in developing countries. There is already a pressing need to facilitate
innovative ways of offering training and education in research ethics. As well as supporting 
and enhancing current training programmes it will be essential to build up a cadre of trainers 
located in developing scountries, as well as establishing a process of mentoring for local eth-
ics committees (Bhutta 2004).
•	 In addition, further ways of providing financial support to ethics committees in 
developing countries need to be found.
•	 Applying post-study obligations to all types of research without further refine-
ment would be unlikely to achieve broad acceptance of the duties entailed and 
may even lead to new injustices, in particular if valuable publicly funded 
research tailored to Type III diseases10 were abandoned in developing countries. 
Such research could attract exemptions or waivers from post-study obligations, 
as they already comply with fairness requirements.
•	 The tension between benefit sharing and undue inducement needs to be resolved 
for developing countries. The ideal solution would be the global success of the 
fair exchange model between the health care industry, human research partici-
pants and national governments: human research participants show solidarity 
with others (Knoppers 2000; Berg and Chadwick 2001) by taking part in medi-
cal research and are rewarded, like their fellow citizens, with the fruits of medi-
cal progress, generated through industry and partly funded through national 
governments. In such circumstances, concerns about undue inducements would 
be restricted to substantial monetary rewards and other excessive remunerations.
•	 However, as long as this ideal solution remains no more than an aspira-
tion, ways must be found to avoid the exploitation of research participants in 
10
 Type III diseases are those that occur exclusively or overwhelmingly in poor countries.
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developing countries. One such way is to promote access to health care, as well 
as health care training and education, as a standard and legitimate means of 
sharing benefits for research involving minimal risk. To substantiate this recom-
mendation, one could argue that CIOMS supports it indirectly.
When research interventions or procedures that do not hold out the prospect of direct 
benefit present more than minimal risk, all parties involved in the research – sponsors, 
investigators and ethical review committees – in both funding and host countries should 
be careful to avoid undue material inducement (CIOMS 2002: guideline 7, commentary).
•	 In other words, concerns about undue inducement – which essentially aim to 
avoid a situation where participants take risks with their health, against their 
better judgement, in order to qualify for a benefit – are much less problematic 
when a research intervention poses only minimal risk (for example, sample 
donation). In such cases, the provision of health care (however extensive and 
for however long) should not count as an undue inducement. On the contrary, it 
should count as desirable benefit sharing.
•	 Overall, it is important not to lose sight of the bigger picture when discussing 
benefit sharing. Research sponsors and funders are, after all, not the main duty 
bearers for providing health care to those who cannot afford it. It is essential 
to support and strengthen the capacity of national governments to discharge 
their duties with regard to the right to health. Such support efforts should go 
far beyond the monitoring of post-study obligations through research ethics 
committees and concentrate on other factors, for instance the fact that – with 
reference to the Agreement on Trade-Related Aspects of Intellectual Property 
Rights (TRIPS) and free trade agreements (FTAs) – ‘TRIPS and FTAs have had 
an adverse impact on prices and availability of medicines, making it difficult for 
countries to comply with their obligations to respect, protect, and fulfil the right 
to health’ (Grover 2009: paragraph 94). The next chapter will introduce a reform 
plan which aims to contribute a part-solution to this problem.
•	 Last, but not least, Martin Luther King’s country of birth, the United States, 
should be put under pressure for opting out of the benefit-sharing frameworks of 
the CBD and the Declaration of Helsinki.
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